Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2017	Apr. 03, 2016
Revenue from External Customer [Line Items]
Revenues	[1],[2]	$ 12,779	$ 13,005
Innovative Health and Essential Health [Member]
Revenue from External Customer [Line Items]
Revenues		12,779	13,005
Innovative Health and Essential Health [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,271	1,229
Innovative Health and Essential Health [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	339	396
Innovative Health and Essential Health [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		656	360
Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	7,415	7,033
Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	5,364	5,972
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	2,606	2,800
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		404	411
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		228	236
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		228	256
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues		82	78
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Epi Pen [Member]
Revenue from External Customer [Line Items]
Revenues		81	97
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Zithromax / Zmax [Member]
Revenue from External Customer [Line Items]
Revenues		79	80
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Xalatan Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		77	89
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		68	79
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		66	70
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Xanax/Xanax XR [Member]
Revenue from External Customer [Line Items]
Revenues		55	52
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		1,238	1,352
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	1,552	1,524
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		122	96
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		120	113
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		74	76
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		71	78
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member]
Revenue from External Customer [Line Items]
Revenues		64	69
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		1,100	1,092
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	822	1,090
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	141	218
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	89	96
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		175	172
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		116	178
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		107	156
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		77	127
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		65	66
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		53	76
Biosimilars [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	105	66
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues		78	36
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues		27	30
CentreOne [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	182	188
Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[12]	97	304
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		2,377	2,124
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,131	1,011
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues		564	373
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	249	300
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		239	220
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		63	64
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues		62	51
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues		69	105
Vaccines [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,465	1,570
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevenar family [Member]
Revenue from External Customer [Line Items]
Revenues		1,392	1,509
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		73	62
Oncology [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,347	1,001
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		679	429
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		250	278
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		142	139
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member]
Revenue from External Customer [Line Items]
Revenues		131	0
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		85	101
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		61	55
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		871	947
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		588	733
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		250	197
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member]
Revenue from External Customer [Line Items]
Revenues		9	0
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		24	17
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		507	568
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		149	185
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		130	129
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		104	125
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		56	55
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		67	75
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		$ 848	$ 822

[1] Amounts may not add due to rounding.

[2] Medivation’s and Anacor’s commercial operations are included in our condensed consolidated statements of income, commencing from their respective acquisition dates of September 28, 2016 and June 24, 2016. Therefore, our results of operations for the first quarter of 2016 do not include financial results from Medivation or Anacor. On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The commercial operations of HIS are included in our condensed consolidated statements of income through February 2, 2017 and, therefore, our financial results for the first quarter of 2017 reflect approximately one month of legacy HIS domestic operations and approximately two months of legacy HIS international operations, while financial results in our condensed consolidated statements of income for the first quarter of 2016 reflect three months of legacy HIS global operations.

[3] Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.

[4] Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.

[5] The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Medivation and Anacor commercial operations. Medivation’s and Anacor’s commercial operations are included in IH’s operating results in our consolidated statements of income, commencing from their respective acquisition dates of September 28, 2016 and June 24, 2016. Therefore, our first-quarter 2016 results of operations, and IH’s operating results, do not include financial results from Medivation or Anacor. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.

[6] The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, HIS (through February 2, 2017), Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in EH’s operating results through February 2, 2017, and, therefore, financial results for EH for the first quarter of 2017 reflect approximately one month of legacy HIS domestic operations and approximately two months of legacy HIS international operations, while financial results for EH for the first quarter of 2016 reflect three months of legacy HIS global operations.

[7] Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above.

[8] Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).

[9] Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra.

[10] Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle East markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle East markets.

[11] Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis.

[12] HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.